Next Phase Newsletter

A global life sciences advisory and venture capital firm provides strategic advisory services alongside direct venture investments in biotechnology, pharmaceutical, medical device, and digital health companies. The firm maintains an international investment portfolio spanning multiple healthcare sectors and collaborates with companies and institutions across North America, Europe, and other global markets. In addition to capital, the firm supports portfolio companies through strategic guidance in product development, regulatory planning, and commercialization strategy.  

The firm invests across therapeutics, medical technologies, diagnostics, digital health, and platform-based innovations that address major unmet clinical needs. Areas of activity include oncology, infectious diseases, neurology, immunology, women’s health, and device-enabled interventions, as well as computational and data-driven healthcare approaches. The firm prioritizes opportunities with strong scientific rationale, translational potential, and clear regulatory and commercial pathways.  

From a company and management team perspective, the firm partners with teams demonstrating scientific credibility, disciplined development planning, and operational capability to advance programs efficiently through key milestones. The firm values strong intellectual property positions, robust preclinical or clinical data packages, and clearly defined global development and market entry strategies. Leveraging its combined investment and advisory capabilities, the firm supports companies through integrated guidance across R&D, regulatory strategy, clinical development, business development, and commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: technology, health, business, finance, investing

An investment manager founded in 2021 and headquartered in Asia primarily operates as a fund-of-funds, allocating capital to healthcare and life sciences-focused investment vehicles including venture capital, private equity, and public market funds. In addition to fund commitments, the firm also participates directly in company financings through special purpose vehicles.  

For direct investments, the firm takes a flexible approach but typically participates in later financing rounds after gaining a deeper understanding of the company and its development trajectory. The firm has no specific preference between leading or co-investing and evaluates opportunities globally.  

The firm is broadly interested in companies operating in biotechnology, medical technology, and digital health.  

The firm does not impose specific requirements regarding company structure or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a joint venture investment vehicle established by a family office and a strategic investment partner. The firm focuses on later-stage medical device opportunities, particularly Series A and Series B companies approaching regulatory approval. The firm primarily evaluates opportunities in the United States and Western Europe, while remaining open to select companies based in Asia. Typical check sizes range from approximately $500K to $1.5M, and the firm prefers to lead transactions. The firm may also co-invest alongside affiliated investment vehicles to support later-stage, revenue-generating companies that demonstrate a clear path to exit within a relatively short time horizon. Through long-standing industry relationships, the firm helps introduce portfolio companies into a specialized medical technology ecosystem to accelerate growth and commercialization.  

The firm evaluates opportunities across medical device categories but maintains a strong focus on implantable technologies. Core areas of interest include neuromuscular and musculoskeletal indications, particularly orthopedic and spine implants. The firm also reviews opportunities in cardiology, vascular and peripheral devices, surgical technologies, and select oncology-related technologies. Companies should typically be approaching regulatory approval and demonstrate validated technology and clinical utility.  

From a company and management team perspective, the firm requires board representation and at minimum takes an observer seat in portfolio companies. The firm seeks companies with proven technology, clear regulatory pathways, and strong commercial potential within established clinical markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a family-run investment and commercialization vehicle focused on early-stage life sciences and technology opportunities. The firm is flexible in structuring transactions, with prior investments ranging from minority participation in financing rounds to in-licensing entire therapeutic programs.  

The firm specializes in therapeutic opportunities, with a particular emphasis on rare diseases. The firm prioritizes indications where the pathophysiology is well understood, the development pathway is straightforward, and there is a clearly defined unmet medical need. The firm is also attracted to opportunities that are de-risked, including reformulation strategies and drug repurposing approaches.  

From a company and management team perspective, the firm has a strong preference for experienced leadership teams with proven track records of value creation and execution.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A family office invests in both private and public life science and healthcare companies. The firm typically writes six-figure checks for companies approaching clinical development. While historically focused on North America, the firm remains open to evaluating opportunities globally. The firm invests across therapeutics, diagnostics, digital health, and medical devices.  

The firm is generally disease-agnostic, with particular interest in ophthalmology, inflammation, and dermatology. The firm is also increasingly exploring opportunities at the intersection of technology and healthcare, including AI-enabled platforms that enhance patient management and diagnostic workflows. Although oncology is not a core focus, the firm may selectively evaluate certain indications.  

From a stage perspective, the firm reviews opportunities as early as pre-IND and generally prefers programs through Phase II development. The firm seeks evidence of technical and regulatory de-risking, including proof-of-concept data, early efficacy signals, and clearly defined regulatory pathways.  

The firm does not impose strict requirements on company or management team composition but values teams that demonstrate regulatory expertise and the ability to execute within clinical and compliance-driven environments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a publicly listed global biopharmaceutical company headquartered in Asia with a strong presence across major international markets. The firm is recognized for its capabilities in large-scale biologics development and manufacturing and has built a substantial commercial footprint worldwide. The firm pursues external innovation through equity investments, research collaborations, and in-licensing arrangements to strengthen and diversify its pipeline.  

The firm operates broadly across therapeutics and biopharmaceutical innovation, with established expertise in antibody-based medicines, follow-on biologics, and next-generation biologic platforms. The firm continues to expand into novel therapeutic programs across immunology, oncology, infectious diseases, and other high-need areas. In addition to maintaining a portfolio of established biologic products, the firm is actively enhancing its innovative pipeline through internal research, strategic partnerships, and selective in-licensing of differentiated biologic assets, including immune-modulating therapies and advanced antibody formats. The firm is open to opportunities across development stages, with interest in early and mid-stage programs.  

The firm seeks partnerships that align with its long-term biologics strategy and leverage its global development, regulatory, and manufacturing infrastructure. The firm evaluates opportunities based on strong scientific rationale, differentiated clinical positioning, scalable manufacturing feasibility, and global market potential. The firm prefers to collaborate with teams that demonstrate rigorous data generation, defensible intellectual property, and the operational capability to execute international development and commercialization strategies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology